Idiopathic Pulmonary Fibrosis (IPF)Phase 2ARGiNAUTNCT07652658

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

A Phase 2 study testing AZD8965 low dose, AZD8965 medium dose and AZD8965 high dose in people with Idiopathic Pulmonary Fibrosis (IPF), run by AstraZeneca at 198 sites in 23 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy. Read more about this study

Who is it for?: Ages 40 years and older
Conditions the study is for: Idiopathic Pulmonary Fibrosis (IPF)
What is being tested?: AZD8965 low dose, AZD8965 medium dose and AZD8965 high dose
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 359 participants
Where: 198 sitesin 23 countries
Study dates: 11 Jun 2026to 18 Sep 2028
Phase: Phase 2
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age ≥ 40 years
IPF diagnosis
Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
FVC ≥ 45% predicted of normal
DLCO corrected for hemoglobin ≥ 25% predicted of normal

Who cannot join

ILD other than IPF
The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
Acute exacerbation of IPF
Lower respiratory tract infection requiring treatment
Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
Heart failure
History of organ transplantation or is likely to receive lung transplantation

Trial locations and contacts

198 sites in 23 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

198 sites in 23 countries

United States36 sites, 35 recruiting

Research Site
Ann Arbor, Michigan, 48109
Not yet recruiting
Research Site
Atlanta, Georgia, 30322
Recruiting
Research Site
Aurora, Colorado, 80045
Not yet recruiting
Research Site
Baltimore, Maryland, 21201
Not yet recruiting
Research Site
Birmingham, Alabama, 35205
Not yet recruiting
Research Site
Boise, Idaho, 83702
Recruiting
Research Site
Boston, Massachusetts, 02114
Not yet recruiting
Research Site
Burlington, Vermont, 05401
Not yet recruiting
Research Site
Champaign, Illinois, 61820
Recruiting
Research Site
Charleston, South Carolina, 29425
Not yet recruiting
Research Site
Chicago, Illinois, 60611
Not yet recruiting
Research Site
Cincinnati, Ohio, 45267
Not yet recruiting
Research Site
Dallas, Texas, 75254
Not yet recruiting
Research Site
Denver, Colorado, 80206
Recruiting
Research Site
Detroit, Michigan, 48202
Not yet recruiting
Research Site
El Paso, Texas, 79902
Recruiting
Research Site
Fountain Hill, Pennsylvania, 18015
Recruiting
Research Site
Greensboro, North Carolina, 27403
Not yet recruiting
Research Site
Houston, Texas, 77030
Not yet recruiting
Research Site
Kansas City, Kansas, 66160
Not yet recruiting
Research Site
Lexington, Kentucky, 40536
Not yet recruiting
Research Site
Loma Linda, California, 92350
Not yet recruiting
Research Site
Los Angeles, California, 90033
Not yet recruiting
Research Site
New York, New York, 10017
Not yet recruiting
Research Site
New York, New York, 10029
Recruiting
Research Site
Newport Beach, California, 92663
Recruiting
Research Site
Ocala, Florida, 34470
Withdrawn
Research Site
Oklahoma City, Oklahoma, 73104
Not yet recruiting
Research Site
Philadelphia, Pennsylvania, 19104
Not yet recruiting
Research Site
Philadelphia, Pennsylvania, 19140
Recruiting
Research Site
Phoenix, Arizona, 85006
Not yet recruiting
Research Site
Phoenix, Arizona, 85032
Recruiting
Research Site
Richmond, Virginia, 23298
Not yet recruiting
Research Site
Sacramento, California, 95817
Not yet recruiting
Research Site
Stanford, California, 94305
Not yet recruiting
Research Site
Weston, Florida, 33331
Not yet recruiting

Other trials in United States

Germany18 sites, 15 recruiting

Research Site
Bonn, 53127
Recruiting
Research Site
Coswig, 01640
Not yet recruiting
Research Site
Essen, 45239
Recruiting
Research Site
Freiburg im Breisgau, 79106
Recruiting
Research Site
Fulda, 36043
Not yet recruiting
Research Site
Giessen, 35392
Recruiting
Research Site
Hamburg, 20251
Not yet recruiting
Research Site
Hanover, 30459
Recruiting
Research Site
Heidelberg, 69126
Withdrawn
Research Site
Hemer, 58675
Recruiting
Research Site
Konstanz, 78464
Withdrawn
Research Site
Leipzig, 04103
Not yet recruiting
Research Site
Lübeck, 23538
Not yet recruiting
Research Site
Marburg, 35037
Recruiting
Research Site
Munich, 81377
Recruiting
Research Site
Stuttgart, 70376
Recruiting
Research Site
Witten, 58452
Withdrawn
Research Site
Wuppertal-Barmen, 42283
Recruiting

Other trials in Germany

China16 sites, 15 recruiting

Research Site
Beijing, 100000
Recruiting
Research Site
Beijing, 100029
Recruiting
Research Site
Beijing, 100730
Not yet recruiting
Research Site
Changchun, 130041
Recruiting
Research Site
Changsha, 430033
Not yet recruiting
Research Site
Chengdu, 610041
Recruiting
Research Site
Chengdu, 610078
Recruiting
Research Site
Guangzhou, 510220
Recruiting
Research Site
Lanzhou, 730030
Not yet recruiting
Research Site
Nanchang, 330000
Not yet recruiting
Research Site
Nanjing, 2100008
Recruiting
Research Site
Shanghai, 200433
Recruiting
Research Site
Shenyang, 110015
Withdrawn
Research Site
Wuhan, 430030
Recruiting
Research Site
Xuzhou, 221000
Recruiting
Research Site
Zhengzhou, 450000
Not yet recruiting

Other trials in China

Japan15 sites, 15 recruiting

Research Site
Fukuoka, 810-8563
Recruiting
Research Site
Hachioji-shi, 193-0998
Recruiting
Research Site
Hamamatsu, 431-3192
Not yet recruiting
Research Site
Hiroshima, 734-8530
Recruiting
Research Site
Kakogawa-shi, 675-8611
Recruiting
Research Site
Kumagaya-shi, 360-0197
Recruiting
Research Site
Kumamoto, 861-4193
Not yet recruiting
Research Site
Matsusaka-shi, 515-8544
Recruiting
Research Site
Sakaishi, 591-8555
Not yet recruiting
Research Site
Sendai, 980-8574
Not yet recruiting
Research Site
Seto-shi, 489-8642
Not yet recruiting
Research Site
Shimotsuke-shi, 329-0498
Not yet recruiting
Research Site
Shinjuku-ku, 162-8655
Recruiting
Research Site
Yokohama, 236-0037
Recruiting
Research Site
Yokohama, 236-0051
Not yet recruiting

Other trials in Japan

Mexico9 sites, 9 recruiting

Research Site
Benito Juárez, 03330
Not yet recruiting
Research Site
Chihuahua City, 31203
Not yet recruiting
Research Site
Coyocan, 04330
Not yet recruiting
Research Site
León, 37160
Not yet recruiting
Research Site
Mérida, 97130
Not yet recruiting
Research Site
Monterrey, 64460
Not yet recruiting
Research Site
Monterrey, 64465
Not yet recruiting
Research Site
Oaxaca City, 68000
Not yet recruiting
Research Site
Pachuca, 42070
Not yet recruiting

Other trials in Mexico

Bulgaria8 sites, 6 recruiting

Research Site
Haskovo, 6300
Withdrawn
Research Site
Plovdiv, 4001
Not yet recruiting
Research Site
Rousse, 7000
Recruiting
Research Site
Rousse, 7002
Not yet recruiting
Research Site
Sofia, 1000
Not yet recruiting
Research Site
Sofia, 1618
Recruiting
Research Site
Sofia, 1680
Withdrawn
Research Site
Sofia, 1756
Not yet recruiting

Other trials in Bulgaria

Canada8 sites, 8 recruiting

Research Site
Ajax, Ontario, L1S 2J5
Recruiting
Research Site
Burlington, Ontario, L7N 3V2
Recruiting
Research Site
Kingston, Ontario, K7M 4E7
Recruiting
Research Site
North York, Ontario, M2K 1E1
Recruiting
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4
Recruiting
Research Site
Sherbrooke, Quebec, J1H 5N4
Recruiting
Research Site
Sherwood Park, Alberta, T8H 2M7
Not yet recruiting
Research Site
Vancouver, British Columbia, V5Z 1M9
Not yet recruiting

Other trials in Canada

France8 sites, 8 recruiting

Research Site
Angers, 49933
Not yet recruiting
Research Site
Brest, 29609
Recruiting
Research Site
Bron, 69677
Recruiting
Research Site
Montpellier, 34295
Not yet recruiting
Research Site
Nice, 6000
Recruiting
Research Site
Paris, 75877
Not yet recruiting
Research Site
Rennes, 35033
Not yet recruiting
Research Site
Tours, 37000
Recruiting

Other trials in France

Italy8 sites, 8 recruiting

Research Site
Foggia, 71100
Recruiting
Research Site
Forlì, 47121
Not yet recruiting
Research Site
Modena, 41124
Not yet recruiting
Research Site
Monza, 20900
Not yet recruiting
Research Site
Pavia, 27100
Recruiting
Research Site
Rozzano, 20089
Recruiting
Research Site
Siena, 53100
Recruiting
Research Site
Torino, 10126
Not yet recruiting

Other trials in Italy

Taiwan8 sites, 8 recruiting

Research Site
Kaohsiung City, 80756
Recruiting
Research Site
Kaohsiung City, 824
Recruiting
Research Site
Taichung, 40705
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taipei, 11220
Recruiting
Research Site
Taipei, 11696
Recruiting
Research Site
Taoyuan, 333
Recruiting
Research Site
Yunlin, 640
Recruiting

Other trials in Taiwan

Greece7 sites, 7 recruiting

Research Site
Athens, 11527
Not yet recruiting
Research Site
Athens, 11527
Recruiting
Research Site
Athens, 12462
Recruiting
Research Site
Heraklion, 71110
Recruiting
Research Site
Ioannina, 45500
Recruiting
Research Site
Pátrai, 26504
Not yet recruiting
Research Site
Thessaloniki, 57010
Recruiting

Other trials in Greece

Argentina6 sites, 5 recruiting

Research Site
Alberdi, X5033DCE
Not yet recruiting
Research Site
Buenos Aires, 1425
Not yet recruiting
Research Site
Ciudad de Buenos Aires, C1414AIF
Not yet recruiting
Research Site
Florida, B1602DQD
Not yet recruiting
Research Site
Rosario, 2000
Withdrawn
Research Site
San Fernando, B1646EBJ
Not yet recruiting

Other trials in Argentina

Poland6 sites, 4 recruiting

Research Site
Bialystok, 15-044
Recruiting
Research Site
Krakow, 31-202
Withdrawn
Research Site
Lodz, 90-153
Withdrawn
Research Site
Poznan, 60-569
Not yet recruiting
Research Site
Rzeszów, 35-205
Recruiting
Research Site
Warsaw, 02-507
Recruiting

Other trials in Poland

Spain6 sites, 6 recruiting

Research Site
Barcelona, 08036
Not yet recruiting
Research Site
Barcelona, 8025
Not yet recruiting
Research Site
L'Hospitalet de Llobregat, 08907
Not yet recruiting
Research Site
Madrid, 28006
Not yet recruiting
Research Site
Málaga, 29010
Recruiting
Research Site
Valencia, 46010
Recruiting

Other trials in Spain

United Kingdom6 sites, 6 recruiting

Research Site
Bristol, BS105NB
Recruiting
Research Site
Cottingham, HU16 5JQ
Recruiting
Research Site
Edinburgh, EH16 4SA
Recruiting
Research Site
Exeter, EX2 5DW
Recruiting
Research Site
Liverpool, L9 7AL
Recruiting
Research Site
London, SW3 6NP
Recruiting

Other trials in United Kingdom

Chile5 sites, 5 recruiting

Research Site
Providencia, 7500504
Recruiting
Research Site
Santiago, 7750495
Recruiting
Research Site
Talca, 3481349
Recruiting
Research Site
Viña del Mar, 2531172
Recruiting
Research Site
Viña del Mar, 2540488
Recruiting

Other trials in Chile

Israel5 sites, 5 recruiting

Research Site
Ashkelon, 78278
Recruiting
Research Site
Jerusalem, 9103102
Recruiting
Research Site
Kfar Saba, 4428164
Recruiting
Research Site
Petah Tikva, 4941492
Recruiting
Research Site
Rehovot, 76100
Recruiting

Other trials in Israel

South Korea5 sites, 5 recruiting

Research Site
Seongnam-si, 13620
Recruiting
Research Site
Seoul, 02841
Recruiting
Research Site
Seoul, 04401
Recruiting
Research Site
Seoul, 06351
Recruiting
Research Site
Seoul, 5505
Recruiting

Other trials in South Korea

Denmark4 sites, 4 recruiting

Research Site
Aarhus, 8200
Recruiting
Research Site
Copenhagen, 2100
Not yet recruiting
Research Site
Hellerup, 2900
Recruiting
Research Site
Odense C, 5000
Recruiting

Other trials in Denmark

Hungary4 sites, 4 recruiting

Research Site
Budapest, 1083
Not yet recruiting
Research Site
Budapest, 1121
Not yet recruiting
Research Site
Debrecen, 4032
Not yet recruiting
Research Site
Törökbálint, 2045
Recruiting

Other trials in Hungary

South Africa4 sites, 3 recruiting

Research Site
Cape Town, 7700
Recruiting
Research Site
Durban, 4001
Recruiting
Research Site
Parktown West, 2193
Not yet recruiting
Research Site
Somerset West, 7130
Withdrawn

Other trials in South Africa

Australia3 sites, 3 recruiting

Research Site
Camperdown, 2050
Not yet recruiting
Research Site
Port Macquarie, 2444
Recruiting
Research Site
Wollongong, 2500
Recruiting

Other trials in Australia

Netherlands3 sites, 3 recruiting

Research Site
Amsterdam, 1081 HV
Not yet recruiting
Research Site
Heerlen, 6419 PC
Recruiting
Research Site
Nieuwegein, 3435 CM
Recruiting

Other trials in Netherlands

About this study

Official title: A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)

Read the detailed description

This is a Phase IIb, randomized, placebo-controlled, double-blind, parallel-group 24-week study to assess the efficacy, safety and tolerability of three doses of AZD8965 versus placebo administered to participants with IPF. The enrolled participants will include those on stable dose(s) of one or two approved antifibrotic therapies and those who are not taking any antifibrotic therapy. Approximately 360 participants will be randomized across approximately 200 sites globally.

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Being tested: Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
Medical subject headings: Idiopathic Pulmonary Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Placebo for AZD8965Other
Placebo for AZD8965
AZD8965 low doseDrug
AZD8965 low dose
AZD8965 medium doseDrug
AZD8965 medium dose
AZD8965 high doseDrug
AZD8965 high dose

Study groups in NCT07652658
Study group	Role	What they receive
Placebo for AZD8965	Placebo comparator	Placebo for AZD8965 Receives: Other: Placebo for AZD8965
AZD8965 low dose	Experimental	AZD8965 low dose Receives: Drug: AZD8965 low dose
AZD8965 medium dose	Experimental	AZD8965 medium dose Receives: Drug: AZD8965 medium dose
AZD8965 high dose	Experimental	AZD8965 high dose Receives: Drug: AZD8965 high dose

What is being measured

The primary outcome is the main question the study is designed to answer.

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
Measured: at Week 24

Secondary outcomes (7)

Relationship between dose and clinical efficacy of AZD8965 at Week 24
Change from baseline in FVC (in mL)
Measured: Week 24
Change from baseline in FVC at Week 24
Change from baseline in % predicted FVC
Measured: Week 24
Change in rate of decline in FVC at Week 24
Change in rate of decline in FVC (in mL/week)
Measured: Week 24
Number of participants with adverse events (AEs)
Number of participants with AEs
Measured: Up to 25 weeks
Number of participants with serious adverse events (SAEs)
Number of participants with SAEs
Measured: Up to 25 weeks
Number of participants with AEs leading to discontinuation
Number of participants with AEs leading to discontinuation
Measured: Up to 25 weeks
Summary statistics to evaluate the PK of AZD8965
AZD8965 concentrations in plasma
Measured: From baseline to Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

11 Jun 202618 Sep 2028

First posted17 Jun 2026
Study start11 Jun 2026
Primary completion18 Sep 2028 (estimated)
Study completion18 Sep 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Idiopathic Pulmonary Fibrosis (IPF)Studies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 359 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07652658
Sponsor's protocol ID: D6960C00005
Acronym: ARGiNAUT
Status last verified: Oct 2026
First submitted: 5 May 2026
Last updated: 29 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Not yet recruitingPhase 2
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Active, not recruitingPhase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (IPF)
Not yet recruitingPhase 3
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Pulmonary Fibrosis

All Idiopathic Pulmonary Fibrosis (IPF) trials

Study at a glance

From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
ClinicalTrials.gov ID: NCT07652658
Acronym / sponsor ID: ARGiNAUT / D6960C00005
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Phase: Phase 2
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 359 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 11 Jun 2026 (actual)
Primary completion: 18 Sep 2028 (estimated)
Study completion: 18 Sep 2028 (estimated)
First posted: 17 Jun 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
Placebo for AZD8965	Placebo comparator	Other: Placebo for AZD8965Placebo for AZD8965
AZD8965 low dose	Experimental	Drug: AZD8965 low doseAZD8965 low dose
AZD8965 medium dose	Experimental	Drug: AZD8965 medium doseAZD8965 medium dose
AZD8965 high dose	Experimental	Drug: AZD8965 high doseAZD8965 high dose

Who may qualify

Ages: 40 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Age ≥ 40 years
IPF diagnosis
Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
FVC ≥ 45% predicted of normal
DLCO corrected for hemoglobin ≥ 25% predicted of normal

Key exclusion criteria (7 listed)

ILD other than IPF
The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
Acute exacerbation of IPF
Lower respiratory tract infection requiring treatment
Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Placebo for AZD8965Placebo for AZD8965	Other	Placebo for AZD8965
AZD8965 low doseAZD8965 low dose	Drug	AZD8965 low dose
AZD8965 medium doseAZD8965 medium dose	Drug	AZD8965 medium dose
AZD8965 high doseAZD8965 high dose	Drug	AZD8965 high dose

Primary outcome

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
Time frame: at Week 24
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24

7 secondary outcomes

Relationship between dose and clinical efficacy of AZD8965 at Week 24
Time frame: Week 24
Change from baseline in FVC at Week 24
Time frame: Week 24
Change in rate of decline in FVC at Week 24
Time frame: Week 24
Number of participants with adverse events (AEs)
Time frame: Up to 25 weeks
Number of participants with serious adverse events (SAEs)
Time frame: Up to 25 weeks
Number of participants with AEs leading to discontinuation
Time frame: Up to 25 weeks
Summary statistics to evaluate the PK of AZD8965
Time frame: From baseline to Week 24

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Related trials for Idiopathic Pulmonary Fibrosis (IPF)

RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Not yet recruitingPhase 2
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Active, not recruitingPhase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (IPF)
Not yet recruitingPhase 3
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Pulmonary Fibrosis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

198 sites in 23 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AZD8965 low dose, AZD8965 medium dose and AZD8965 high dose in people with Idiopathic Pulmonary Fibrosis (IPF), run by AstraZeneca at 198 sites in 23 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 198 sites in United States, Germany, China, Japan, Mexico and 18 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24 (time frame: at Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07652658.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.